Home > Cardiopulmonary impact of electronic cigarettes and vaping products: a scientific statement from the American Heart Association.

Rose, Jason J and Krishnan-Sarin, Suchitra and Exil, Vernat J and Hamburg, Naomi M and Fetterman, Jessica L and Ichinose, Fumito and Perez-Pinzon, Miguel A and Rezk-Hanna, Mary and Williamson, Eric (2023) Cardiopulmonary impact of electronic cigarettes and vaping products: a scientific statement from the American Heart Association. Circulation, 148, (8), pp. 703-728. https://doi.org/10.1161/CIR.0000000000001160.

External website: https://www.ahajournals.org/doi/10.1161/CIR.000000...

Vaping and electronic cigarette (e-cigarette) use have grown exponentially in the past decade, particularly among youth and young adults. Cigarette smoking is a risk factor for both cardiovascular and pulmonary disease. Because of their more limited ingredients and the absence of combustion, e-cigarettes and vaping products are often touted as safer alternative and potential tobacco-cessation products. The outbreak of e-cigarette or vaping product use-associated lung injury in the United States in 2019, which led to >2800 hospitalizations, highlighted the risks of e-cigarettes and vaping products. Currently, all e-cigarettes are regulated as tobacco products and thus do not undergo the premarket animal and human safety studies required of a drug product or medical device. Because youth prevalence of e-cigarette and vaping product use was as high as 27.5% in high school students in 2019 in the United States, it is critical to assess the short-term and long-term health effects of these products, as well as the development of interventional and public health efforts to reduce youth use. The objectives of this scientific statement are (1) to describe and discuss e-cigarettes and vaping products use patterns among youth and adults; (2) to identify harmful and potentially harmful constituents in vaping aerosols; (3) to critically assess the molecular, animal, and clinical evidence on the acute and chronic cardiovascular and pulmonary risks of e-cigarette and vaping products use; (4) to describe the current evidence of e-cigarettes and vaping products as potential tobacco-cessation products; and (5) to summarize current public health and regulatory efforts of e-cigarettes and vaping products. It is timely, therefore, to review the short-term and especially the long-term implications of e-cigarettes and vaping products on cardiopulmonary health. Early molecular and clinical evidence suggests various acute physiological effects from electronic nicotine delivery systems, particularly those containing nicotine. Additional clinical and animal-exposure model research is critically needed as the use of these products continues to grow.


Item Type
Article
Publication Type
International, Open Access, Article
Drug Type
Tobacco / Nicotine
Intervention Type
Prevention, Harm reduction
Date
2023
Identification #
https://doi.org/10.1161/CIR.0000000000001160
Page Range
pp. 703-728
Publisher
American Heart Association
Volume
148
Number
8
EndNote

Repository Staff Only: item control page